208 related articles for article (PubMed ID: 36880250)
1. Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition.
Sano M; Cummings J; Auer S; Bergh S; Fischer CE; Gerritsen D; Grossberg G; Ismail Z; Lanctôt K; Lapid MI; Mintzer J; Palm R; Rosenberg PB; Splaine M; Zhong K; Zhu CW
Int Psychogeriatr; 2024 Apr; 36(4):238-250. PubMed ID: 36880250
[TBL] [Abstract][Full Text] [Related]
2. Agitation in Cognitive Disorders: Use of the National Alzheimer's Coordinating Center Uniform Data Set (NACC-UDS) to Evaluate International Psychogeriatric Association Definition.
Sano M; Zhu CW; Neugroschl J; Grossman HT; Schimming C; Aloysi A
Am J Geriatr Psychiatry; 2022 Nov; 30(11):1198-1208. PubMed ID: 35562259
[TBL] [Abstract][Full Text] [Related]
3. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition.
Cummings J; Mintzer J; Brodaty H; Sano M; Banerjee S; Devanand DP; Gauthier S; Howard R; Lanctôt K; Lyketsos CG; Peskind E; Porsteinsson AP; Reich E; Sampaio C; Steffens D; Wortmann M; Zhong K;
Int Psychogeriatr; 2015 Jan; 27(1):7-17. PubMed ID: 25311499
[TBL] [Abstract][Full Text] [Related]
4. Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm.
Cummings J; Sano M; Auer S; Bergh S; Fischer CE; Gerritsen D; Grossberg G; Ismail Z; Lanctôt K; Lapid MI; Mintzer J; Palm R; Rosenberg PB; Splaine M; Zhong K; Zhu CW
Int Psychogeriatr; 2024 Apr; 36(4):251-262. PubMed ID: 36876335
[TBL] [Abstract][Full Text] [Related]
5. Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria.
De Mauleon A; Ismail Z; Rosenberg P; Miller D; Cantet C; O'Gorman C; Vellas B; Lyketsos C; Soto M
Alzheimers Dement; 2021 Oct; 17(10):1687-1697. PubMed ID: 34132461
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.
De Mauleon A; Delrieu J; Cantet C; Vellas B; Andrieu S; Rosenberg PB; Lyketsos CG; Soto Martin M
J Prev Alzheimers Dis; 2021; 8(2):199-209. PubMed ID: 33569568
[TBL] [Abstract][Full Text] [Related]
7. Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition.
Cummings J; Pinto LC; Cruz M; Fischer CE; Gerritsen DL; Grossberg GT; Hwang TJ; Ismail Z; Jeste DV; Koopmans R; Lanctot KL; Mateos R; Peschin S; Sampaio C; Tsuang D; Wang H; Zhong K; Bain LJ; Sano M
Am J Geriatr Psychiatry; 2020 Dec; 28(12):1256-1269. PubMed ID: 32958332
[TBL] [Abstract][Full Text] [Related]
8. The expert consensus guideline series. Treatment of behavioral emergencies 2005.
Allen MH; Currier GW; Carpenter D; Ross RW; Docherty JP;
J Psychiatr Pract; 2005 Nov; 11 Suppl 1():5-108; quiz 110-2. PubMed ID: 16319571
[TBL] [Abstract][Full Text] [Related]
9. Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus.
Kales HC; Lyketsos CG; Miller EM; Ballard C
Int Psychogeriatr; 2019 Jan; 31(1):83-90. PubMed ID: 30068400
[TBL] [Abstract][Full Text] [Related]
10. 24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone.
Ruthirakuhan M; Herrmann N; Andreazza AC; Verhoeff NPLG; Gallagher D; Black SE; Kiss A; Lanctôt KL
J Alzheimers Dis; 2019; 71(1):21-31. PubMed ID: 31322567
[TBL] [Abstract][Full Text] [Related]
11. Commentary on Agitation in Cognitive Disorders: Use of the National Alzheimer's Coordinating Center Uniform Data Set (NACC-UDS) to Evaluate International Psychogeriatric Association Definition.
Fischer CE
Am J Geriatr Psychiatry; 2022 Nov; 30(11):1209-1211. PubMed ID: 35641401
[No Abstract] [Full Text] [Related]
12. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia.
Halpern R; Seare J; Tong J; Hartry A; Olaoye A; Aigbogun MS
Int J Geriatr Psychiatry; 2019 Mar; 34(3):420-431. PubMed ID: 30430642
[TBL] [Abstract][Full Text] [Related]
13. Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.
Davies SJ; Burhan AM; Kim D; Gerretsen P; Graff-Guerrero A; Woo VL; Kumar S; Colman S; Pollock BG; Mulsant BH; Rajji TK
J Psychopharmacol; 2018 May; 32(5):509-523. PubMed ID: 29338602
[TBL] [Abstract][Full Text] [Related]
14. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial.
Ruthirakuhan MT; Herrmann N; Gallagher D; Andreazza AC; Kiss A; Verhoeff NPLG; Black SE; Lanctôt KL
Contemp Clin Trials Commun; 2019 Sep; 15():100385. PubMed ID: 31338476
[TBL] [Abstract][Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer's Disease: Focus on Agitation and Aggression. A Report from the EU/US/CTAD Task Force.
Soto M; Abushakra S; Cummings J; Siffert J; Robert P; Vellas B; Lyketsos CG;
J Prev Alzheimers Dis; 2015 Sep; 2(3):184-188. PubMed ID: 26413494
[TBL] [Abstract][Full Text] [Related]
17. The Symptoms Targeted for Monitoring in a Web-Based Tracking Tool by Caregivers of People With Dementia and Agitation: Cross-Sectional Study.
Rockwood K; Sanon Aigbogun M; Stanley J; Wong H; Dunn T; Chapman CAT; Howlett SE; Miguelez M; McGarrigle L; Baker RA
J Med Internet Res; 2019 Jun; 21(6):e13360. PubMed ID: 31254339
[TBL] [Abstract][Full Text] [Related]
18. Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research.
Fischer CE; Ismail Z; Youakim JM; Creese B; Kumar S; Nuñez N; Ryan Darby R; Di Vita A; D'Antonio F; de Lena C; McGeown WJ; Ramit R; Rasmussen J; Bell J; Wang H; Bruneau MA; Panegyres PK; Lanctôt KL; Agüera-Ortiz L; Lyketsos C; Cummings J; Jeste DV; Sano M; Devanand DP; Sweet RA; Ballard C
J Alzheimers Dis; 2020; 73(3):1143-1156. PubMed ID: 31884469
[TBL] [Abstract][Full Text] [Related]
19. A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
Banerjee S; Farina N; Henderson C; High J; Stirling S; Shepstone L; Fountain J; Ballard C; Bentham P; Burns A; Fox C; Francis P; Howard R; Knapp M; Leroi I; Livingston G; Nilforooshan R; Nurock S; O'Brien J; Price A; Thomas AJ; Swart AM; Telling T; Tabet N
Health Technol Assess; 2023 Oct; 27(23):1-108. PubMed ID: 37929672
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
